Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zymeworks Inc. (Nasdaq: ZYME) SEC filings page on Stock Titan brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and proxy materials. These documents provide detailed information on financial results, material events, governance matters, and strategic initiatives for this global biotechnology and clinical-stage biopharmaceutical company.
Through its 8-K filings, Zymeworks reports items such as quarterly financial results, material clinical and regulatory milestones, leadership and board changes, share repurchase authorizations, and strategic initiatives related to its asset and royalty aggregation strategy. For example, recent 8-Ks describe positive topline Phase 3 HERIZON-GEA-01 results for Ziihera ® (zanidatamab-hrii), the launch of a share repurchase program, and updates on licensed products and healthcare assets. Other 8-Ks address decisions on specific pipeline programs, such as the voluntary discontinuation of clinical development for ZW171, and amendments to financing instruments like pre-funded warrants.
The company’s definitive proxy statement on Form DEF 14A offers additional insight into Zymeworks’ governance structure, board composition, committee responsibilities, executive compensation practices, and matters submitted to stockholders for approval. Together, these filings help investors understand how Zymeworks oversees its integrated model of internal R&D and royalty-driven asset management.
On Stock Titan, these SEC filings are updated as they become available from EDGAR and are paired with AI-powered summaries that highlight key points, such as revenue drivers, material clinical events, capital structure changes, and governance decisions. Users can quickly scan current and historical filings to track developments affecting Zymeworks’ licensed assets, pipeline programs, cash resources, and shareholder-related actions, without needing to read every page of the underlying documents.
Zymeworks Inc. reported a first-quarter 2026 net loss of $44.2 million, wider than the prior year, as collaboration revenue fell to $2.4 million from milestone-heavy Q1 2025. Operating expenses were stable at $49.5 million, with research and development of $34.5 million and general and administrative of $15.1 million.
Cash, cash equivalents and marketable securities rose to $403.8 million as of March 31, 2026, helped by a $250.0 million non‑recourse term loan obtained through monetizing 30% of future Ziihera royalties, recorded as a $246.5 million liability. The company continued its share repurchase strategy, buying back 3.2 million shares for $76.6 million in the quarter. Zymeworks highlights upcoming regulatory milestones for Ziihera in HER2‑positive gastroesophageal cancers and ongoing development of its ADC and multispecific antibody pipeline.
Zymeworks Inc. reported first quarter 2026 results, with revenue of $2.4 million, down from $27.1 million a year earlier as prior non-recurring clinical milestone payments rolled off and collaboration and royalty revenue became the main drivers.
R&D expense was $34.5 million and G&A was $15.1 million, both slightly lower year over year, leading to a net loss of $44.2 million versus $22.6 million in 2025. Adjusted gross operating expense (non-GAAP) declined to $42.6 million from $46.3 million.
The company ended March 31, 2026 with $403.8 million in cash, cash equivalents and marketable securities and reiterated guidance for approximately $300 million in aggregate adjusted gross operating expenses over 2026–2028. It expects 2026 adjusted gross operating expenses to be about 20% lower than 2025 on a non-GAAP basis.
Zymeworks highlighted regulatory momentum for partnered HER2 antibody Ziihera (zanidatamab-hrii), including U.S. FDA Priority Review for first-line HER2-positive GEA with an August 25, 2026 PDUFA date and sBLA acceptances in China. Potential approval milestones across territories total $440 million.
The company continued to advance wholly owned ADC ZW191, reporting Phase 1 ovarian cancer data with confirmed objective response rates above 50% and high disease control rates, and presented a new RAS inhibitor ADC platform. It also used $95.8 million to repurchase 3.93 million shares under a $125 million buyback, leaving about 73.0 million shares outstanding.
Zymeworks Inc. reports a Schedule 13G filing showing Perceptive-linked holders beneficially own 3,974,579 shares of Common Stock. The filing states this equals 5.4% of the class based on 73,749,607 shares outstanding as of February 26, 2026. Perceptive Life Sciences Master Fund directly holds the shares; Perceptive Advisors and Joseph Edelman are reported as investment manager and managing member, respectively.
Zymeworks Inc. reported that officer Adam Schayowitz received new equity awards as part of his compensation. On April 9, 2026, he was granted stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036. These options vest 25% on the first anniversary of the grant and the rest in 36 monthly installments.
He also received 47,000 restricted stock units that vest in four equal annual installments, plus up to 76,000 performance stock units. The performance units can be earned between 50% and 200% of a 38,000-unit target based on cumulative total shareholder return over a three-year period ending on January 12, 2029, subject to continued service and specific TSR goals.
Zymeworks Inc. granted equity-based compensation to EVP and Chief Business Officer Scott Platshon. He received stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036, which vest 25% after one year and monthly thereafter.
Platshon was also granted 47,000 restricted stock units that vest in four equal annual installments, each RSU delivering one share of common stock upon vesting. In addition, he received 76,000 performance stock units, representing the maximum number that may be earned based on cumulative total shareholder return goals over a three-year performance period ending on January 12, 2029, with 50%–200% of a 38,000-unit target earnable depending on performance.
Zymeworks Inc. disclosed initial equity holdings for executive Adam Schayowitz. He holds stock options covering 167,000 shares of common stock with an exercise price of $16.92 per share, expiring on October 8, 2035. These options were granted on October 9, 2025 and vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Schayowitz also holds 111,111 restricted stock units (RSUs) granted on October 9, 2025. These RSUs vest in three equal annual installments beginning October 9, 2026. Each RSU represents the contingent right to receive one share of Zymeworks common stock upon vesting.
Zymeworks Inc. executive Platshon Scott, EVP and Chief Business Officer, reported initial equity awards in a Form 3. The filing lists stock options covering 167,000 shares of common stock at an exercise price of $22.99 per share, expiring November 17, 2035, plus 111,111 restricted stock units. The options vest 25% on the first anniversary of the November 18, 2025 grant and the remainder in 36 equal monthly installments, while the RSUs vest in three equal annual installments beginning November 18, 2026, with each RSU representing the right to receive one share of common stock upon vesting.
Zymeworks Inc. reported that EVP and Chief Financial Officer Kristin Stafford received new equity compensation awards. She was granted stock options for 178,000 shares of common stock at an exercise price of $25.84 per share, expiring on April 5, 2036. These options vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Stafford also received two restricted stock unit grants. One award covers 119,000 RSUs, vesting in four equal annual installments beginning on the first anniversary of the grant date. The other covers 50,000 RSUs, vesting in three equal annual installments starting on the first anniversary. Each RSU converts into one share of common stock upon vesting, and the filing shows no open-market purchases or sales.
Zymeworks Inc. executive vice president and chief financial officer Kristin Stafford filed an initial Form 3 indicating she currently has no securities beneficially owned in the company. The filing lists both common and derivative securities as having zero shares, reflecting no direct reportable ownership as of the reported date.
Zymeworks Inc. appointed Kristin Stafford, age 44, as Executive Vice President and Chief Financial Officer, effective April 1, 2026. She becomes the company’s principal financial and principal accounting officer. Stafford previously held senior finance and accounting roles at Royalty Pharma, BioPharma Credit, Ernst & Young, iHeartMedia, and Deloitte and serves on Novocure’s board.
She entered into an employment agreement with Zymeworks Biopharmaceuticals Inc. with no fixed term, including change-in-control "parachute" protections structured to avoid excise tax without any tax gross-up from the company. Kenneth Galbraith ceased serving as interim CFO on the start date but continues as Chair, President, and Chief Executive Officer.